ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on…
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly…
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly…
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune…
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune…
Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design…
PITTSBURGH and BRIDGEWATER, N.J., April 28, 2025 /PRNewswire/ -- PredxBio, a pioneer in AI-powered spatial biomarker discovery, today announced a…
Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA®…
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025…
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3%…